CAR T cell therapy for T cell lymphoma shows promise in phase I trial
A first-in-human phase I clinical trial of patients with relapsed or refractory T cell lymphoma found early signals of anti-tumor efficacy and safety.
Read More
Targeting MAPK4 may offer a new therapeutic opportunity for TNBC
MAPK4 seems to be involved in promoting triple-negative breast cancer growth and its resistance to certain therapies.
Read More
Proteomics analysis identifies potential drug targets for aggressive human cancers
Researchers identified proteomic signatures associated with clinical measures of aggressive disease for each of the seven cancer types studied.
Read More
Targeting MAPK4 emerges as a promising therapy for prostate cancer
Inhibiting MAPK4 simultaneously inactivated both androgen receptor and AKT and stopped cancer growth in animal models.
Read More
Fighting cancer with rejection-resistant, ‘off-the-shelf’ therapeutic T cells
Baylor College of Medicine researchers extend the life and effectiveness of off-the-shelf, cancer-fighting immune T cells.
Read More
New insights into the mediators of patient recovery after CAR T cell immunotherapy
Clinical trial of novel personalized CAR T cell immunotherapy provides clues into what mediated exceptional patient recovery.
Read More
From the labs to commercialization: Companies merge to implement Baylor College of Medicine-developed therapies for cancer
Despite major advances in cancer therapy, conventional cancer treatments continue to be associated with devastating side effects for patients and are not always curative. In
Read More